Fairmount Funds Management LLC Allakos Inc. Transaction History

Fairmount Funds Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $240,879 - $3.15 Million	-28,173 Reduced 16.07%	147,189 $1.44 Million
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $1.78 Million - $2.56 Million	23,200 Added 15.25%	175,362 $18.6 Million
Q2 2021 Aug 13, 2021	BUY	$85.37 - $114.1 $384,165 - $513,450	4,500 Added 3.05%	152,162 $13 Million
Q4 2020 Feb 12, 2021	SELL	$79.58 - $152.45 $1.35 Million - $2.59 Million	-17,000 Reduced 10.32%	147,662 $20.7 Million
Q3 2020 Nov 12, 2020	SELL	$66.43 - $90.99 $930,020 - $1.27 Million	-14,000 Reduced 7.84%	164,662 $13.4 Million
Q1 2020 May 08, 2020	BUY	$44.49 - $93.39 $2.22 Million - $4.67 Million	50,000 Added 38.86%	178,662 $7.95 Million
Q4 2019 Feb 12, 2020	BUY	$66.49 - $137.73 $8.55 Million - $17.7 Million	128,662 New	128,662 $12.3 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.